Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years [Phase 3]
Phase 3 trial update evaluating treatment for elderly fit patients (65–80) with newly diagnosed multiple myeloma; status ACTIVE_NOT_RECRUITI…
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma [Phase 2]
Phase 2 trial evaluating Carfilzomib, Lenalidomide, and Dexamethasone in Smoldering Multiple Myeloma has completed and results have been pos…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma [Phase 2]
Phase 2 trial evaluating MGTA-145 with plerixafor for mobilization of hematopoietic stem cells in autologous transplantation for multiple my…
-
CLINICAL_TRIALS trial_result · 2022-09-09Clinical Trial Update: Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
A randomized Phase II study in elderly patients with newly diagnosed multiple myeloma is ongoing, with status not provided in the snippet.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update investigating carfilzomib, cyclophosphamide, and dexamethasone in multiple myeloma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT [Phase 2]
Phase 2 clinical trial evaluating matched unrelated donor stem cell transplantation after dose-reduced conditioning in patients with multipl…
-
CLINICAL_TRIALS trial_result · 2022-09-01Clinical Trial Update: Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating dendritic cell/myeloma fusion vaccines in combination with nivolumab for relapsed multiple myeloma; study terminate…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents [Phase 4]
Phase 4 clinical trial evaluating pneumococcal vaccination in multiple myeloma patients receiving novel therapies has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone [Phase 2]
Phase II study evaluating carfilzomib, pomalidomide, and dexamethasone in multiple myeloma patients who relapsed after prior therapy; status…
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) [Phase 2]
Phase 2 clinical trial update on an anti-BCMA/GPRC5D CAR-T cell therapy for relapsed/refractory multiple myeloma, focusing on safety and eff…
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients [Phase 2]
Phase 2 trial update on PK, safety, and tolerability of peripheral and central infusion of melflufen in relapsed/refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2022-08-12Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT [Phase 2]
A Phase 2 trial evaluating re-induction with carfilzomib, lenalidomide, and dexamethasone followed by a second autologous stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the combination of bortezomib with high-dose melphalan in multiple myeloma has completed enrollment and posted …
-
CLINICAL_TRIALS trial_result · 2022-08-05Clinical Trial Update: HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies [Phase 2]
Phase 2 clinical trial evaluating HLA-compatible related or unrelated donors with CD34+ enriched, T-cell depleted peripheral blood stem cell…
-
CLINICAL_TRIALS trial_result · 2022-08-05Clinical Trial Update: Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating BCMA CAR-T cell therapy in patients with BCMA-positive relapsed or refractory multiple myeloma has completed with r…
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients [Phase 1, Phase 2]
Clinical trial update for FasT CAR-T GC012F in high risk t_NDMM (transplant-eligible and non-durable multiple myeloma) patients across Phase…
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide [Phase 3]
Phase 3 trial of melphalan flufenamide (melflufen) with dexamethasone or pomalidomide-dexamethasone for relapsed/refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating filanesib (ARRY-520) in combination with pomalidomide and dexamethasone for relapsed/refractory multiple…
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for a quadruplet regimen (carfilzomib, lenalidomide, dexamethasone, and elotuzumab) in relapsed/refractory mul…
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase II trial evaluating bevacizumab with bortezomib in relapsed/refractory multiple myeloma; study terminated with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-07-05Clinical Trial Update: Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]
A Phase 2 trial evaluated alternating ixazomib citrate and lenalidomide as maintenance therapy after stem cell transplantation in patients w…
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury [Phase 4]
Phase 4 clinical trial evaluating HFR-SUPRA for treatment of multiple myeloma-related acute kidney injury (not yet recruiting).
-
CLINICAL_TRIALS trial_result · 2022-06-22Clinical Trial Update: A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion [Phase 2]
Phase 2 clinical trial comparing single agent melphalan to BEAM as a preparative regimen for high-dose therapy with autologous stem cell rei…
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment [Phase 2]
Phase 2 trial evaluating daratumumab with bortezomib and dexamethasone in relapsed/refractory multiple myeloma with severe renal impairment …
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on allogeneic hematopoietic stem cell transplantation for multiple myeloma, with results posted.